Edition:
United States

Analyst Research

Report Title Price
Provider : Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

EU approves Roche Holding AG’s Avastin for platinum-resistant recurrent ovarian cancer


Wednesday, 6 Aug 2014 01:00am EDT 

Roche Holding AG:Says EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer.Approval based on results of phase III AURELIA study which involved women with recurrent, platinum-resistant ovarian cancer who received either chemotherapy or Avastin in combination with chemotherapy.